NBRVF (Nabriva Therapeutics) Research & Development: $10.37 Mil (TTM As of Jun. 2023)


NBRVF Nabriva Therapeutics PLC NBRVF
12 GF Score
Price $0.00
View Full Analysis

What is Nabriva Therapeutics Research & Development?

Nabriva Therapeutics NBRVF 12 Research & Development is $10.37 Mil as of Jun. 2023. GuruFocus rates NBRVF with a GF Score™ of 12/100.

Research & Development is the aggregate amount of research and development expenses during the year. Nabriva Therapeutics's Research & Development for the three months ended in Jun. 2023 was $1.09 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 was $10.37 Mil.

Nabriva Therapeutics  (OTCPK:NBRVF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Nabriva Therapeutics Research & Development Related Terms

Nabriva Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Nabriva Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nabriva Therapeutics Research & Development Chart

Nabriva Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 82.29 26.42 15.10 12.63 14.26

Nabriva Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.09 4.03 2.63 2.63 1.09
NBRVF
12GF Score
Nabriva Therapeutics PLC NBRVF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nabriva Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $10.37 Mil mean?
Nabriva Therapeutics (NBRVF) has a Research & Development of $10.37 Mil as of Jun. 2023. Research and development expense is the total cost for research and development activities. View historical data on Nabriva Therapeutics and its competitors.
Is Nabriva Therapeutics' Research & Development too high?
Nabriva Therapeutics' current Research & Development is $10.37 Mil. Overall, Nabriva Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nabriva Therapeutics' Research & Development compare to BXRX and INM?
Nabriva Therapeutics' Research & Development of $10.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Nabriva Therapeutics and its competitors. Nabriva Therapeutics's current Research & Development is $10.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nabriva Therapeutics stock overvalued right now?
Nabriva Therapeutics (NBRVF) has a current Research & Development of $10.37 Mil. The current Research & Development is $10.37 Mil. Nabriva Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Nabriva Therapeutics (NBRVF), the current Research & Development is $10.37 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nabriva Therapeutics Business Description

Address Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. The company is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
12GF Score

Get the complete analysis for NBRVF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price